Literature DB >> 8156000

Degranulation from human eosinophils stimulated with C3a and C5a.

S Takafuji1, K Tadokoro, K Ito, C A Dahinden.   

Abstract

It is unclear what actually induces eosinophil degranulation in vivo. We examined eosinophil cationic protein (ECP) release from normal human eosinophils (Eos) in response to C3a and C5a. C3a and C5a induced remarkable ECP release when Eos were preincubated with cytochalasin B. ECP release induced by C3a or C5a was greater than that induced by PAF at a concentration of 10(-7) M. The ED50 for ECP release was 3 x 10(-8) M and 3 x 10(-9) M for C3a and C5a, respectively. C3a or C5a elicited a rapid and transient rise in [Ca2+]i. These results suggest that C3a and C5a may contribute to hypersensitivity diseases by inducing eosinophil degranulation.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8156000     DOI： 10.1159/000236743

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN： 1018-2438            Impact factor:   2.749


  14 in total

1.  Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Bo H Yoon; Tinnakorn Chaiworapongsa; Edi Vaisbuch; Pooja Mittal; Offer Erez; Francesca Gotsch; Moshe Mazor; Juan P Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

2.  Anaphylatoxins in preterm and term labor.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Jimmy Espinoza; Jyh Kae Nien; Tinnakorn Chaiworapongsa; Joaquin Santolaya-Forgas; Samuel S Edwin; Moshe Mazor
Journal:  J Perinat Med       Date:  2005       Impact factor: 1.901

3.  Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy.

Authors:  Eleazar Soto; Karina Richani; Roberto Romero; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Jyh Kae Nien; Samuel Edwin; Yeon Mee Kim; Joon-Seok Hong; Luis Goncalves; Moshe Mazor
Journal:  J Matern Fetal Neonatal Med       Date:  2005-04

4.  Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies.

Authors:  J Zwirner; O Götze; G Begemann; A Kapp; K Kirchhoff; T Werfel
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

5.  De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation.

Authors:  Meghan L Bellows-Peterson; Ho Ki Fung; Christodoulos A Floudas; Chris A Kieslich; Li Zhang; Dimitrios Morikis; Kathryn J Wareham; Peter N Monk; Owen A Hawksworth; Trent M Woodruff
Journal:  J Med Chem       Date:  2012-04-20       Impact factor: 7.446

6.  Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response.

Authors:  Tao Peng; Liming Hao; Joseph A Madri; Xiao Su; Jack A Elias; Gregory L Stahl; Stephen Squinto; Yi Wang
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

7.  Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue.

Authors:  Andrew P Lane; Quynh-Ai Truong-Tran; Allan Myers; Carol Bickel; Robert P Schleimer
Journal:  Am J Rhinol       Date:  2006 Jan-Feb

8.  C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

Authors:  P J Daffern; P H Pfeifer; J A Ember; T E Hugli
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

9.  The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization.

Authors:  Mike C L Wu; Faith H Brennan; Jason P L Lynch; Susanna Mantovani; Simon Phipps; Rick A Wetsel; Marc J Ruitenberg; Stephen M Taylor; Trent M Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-21       Impact factor: 11.205

Review 10.  Innate immune cells in liver inflammation.

Authors:  Evaggelia Liaskou; Daisy V Wilson; Ye H Oo
Journal:  Mediators Inflamm       Date:  2012-08-09       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.